From the Research
For a post-viral cough, a combination inhaler containing a β-agonist, such as salbutamol, and an anticholinergic agent, such as ipratropium bromide, can effectively reduce cough severity, as demonstrated in a randomized, double-blind, placebo-controlled trial 1.
Key Points to Consider
- The typical dose of salbutamol and ipratropium bromide is 1.875 mg/0.5 mL and 0.375 mg/0.5 mL, respectively, administered via nebulizer for 10 days 1.
- Inhaled corticosteroids, such as fluticasone or budesonide, may also be beneficial in reducing inflammation and relieving symptoms, but their effectiveness in post-viral cough is not as well-established as combination therapy with a β-agonist and anticholinergic agent 2.
- Non-pharmacological remedies, such as honey, glycerol, and herbal agents, may provide some relief, but further studies are needed to confirm their efficacy and safety 3.
Important Considerations
- Proper diagnosis and prescription by a healthcare provider are essential, as post-viral cough can be confused with other conditions like asthma or bronchitis.
- When using an inhaler, proper technique is crucial, including inhaling slowly and deeply, holding your breath for 5-10 seconds, and then exhaling slowly.
- Staying hydrated, using a humidifier, and avoiding irritants like smoke can complement inhaler therapy and help alleviate symptoms.
- Most post-viral coughs resolve within 3-8 weeks, but persistent symptoms warrant medical attention to rule out underlying conditions that may require alternative treatment.